AbbVie (ABBV) Share-based Compensation (2012 - 2026)

AbbVie has disclosed Share-based Compensation across 15 years of filings, most recently posting $444.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 8.29% year-over-year to $444.0 million; the TTM figure through Mar 2026 stood at $989.0 million (up 1.64% YoY), while the FY2025 annual figure was $955.0 million, up 4.83% from the prior year.
• Share-based Compensation advanced to $444.0 million in Q1 2026, from $157.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for ABBV reached as high as $444.0 million in Q1 2026 and fell as low as $107.0 million in Q2 2022.
• The 5-year median for Share-based Compensation is $179.0 million (2023), against an average of $219.3 million.
• Annual changes were most pronounced in 2022 — Share-based Compensation sank 32.7% — and 2023, when it soared 67.29%.
• A 5-year view of Share-based Compensation shows it stood at $132.0 million in 2022, then retreated by 5.3% to $125.0 million in 2023, then soared by 31.2% to $164.0 million in 2024, then declined by 4.27% to $157.0 million in 2025, then surged by 182.8% to $444.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $444.0 million, $157.0 million, and $209.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.